Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

COMPLETE IF KNOWN	
Application Number	10/057,288
Filing Date	01/25/2002
First Named Inventor	CHRISTIAN LARSEN
Art Unit	1644
Examiner Name	GAMBEL, PHILLIP
Attorney Docket Number	D0136 NP

Sheet	1	of	1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Check box if English language translation is attached
	AA	WO2000/40270	07/13/2000	PCT		☐
						☐
						☐
						☐
						☐
						☐
						☐
						☐

Examiner Signature	/Phillip Gambel/	Date Considered	01/21/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

COMPLETE IF KNOWN	
Application Number	10/057,288
Filing Date	01/25/2002
First Named Inventor	CHRISTIAN LARSEN
Art Unit	1644
Examiner Name	GAMBEL, PHILLIP

Sheet	2	of	2	Attorney Docket Number	D0136 NP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	2AA	Gomez, L. et al., "Treatment of Omenn syndrome by bone marrow transplantation", The Journal of Pediatrics, Vol. 127(1), pp. 76-81 (1995)	
	2AB	Ito, T. et al., "Long-term acceptance of major histocompatibility complex-mismatched lung allografts induced by mixed chimerism", Sapporo Medical Journal, Vol. 66(6), pp. 317-326 (1997)	
	2AC	Jabado, N. et al., "Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors", Blood, Vol. 90(12), pp. 4743-8 (1997)	
	2AD	Judge, T.A. et al., "The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival", Journal of Immunology, Vol. 162(4), pp. 1947-51 (1999)	
	2AE	Kapelushnik, J. et al., "Fludarabine-based protocol for haploidentical peripheral blood stem cell transplantation in Hurler syndrome", Journal of Pediatric hematology/oncology: official journal of the American Society of Pediatric Hematology/Oncology, Vol. 22(5), pp. 433-436 (2000)	
	2AF	Tanaka, J. et al., "T-cell co-signalling molecules in graft-versus-host disease", Annals of hematology, Vol. 79(6), pp. 283-90 (2000)	
	2AG	Walters, M.C. et al., "Bone marrow transplantation for sickle cell disease", New England Journal of Medicine, Vol. 335(6), pp. 369-376 (1996)	
	2AH	Zheng, X.X. et al., "CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment", Journal of Immunology, Vol. 162(8), pp. 4983-4990 (1999)	

Examiner Signature	/Phillip Gambel/	Date Considered	01/21/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./